235 related articles for article (PubMed ID: 16211089)
41. VBP1 represses cancer metastasis by enhancing HIF-1α degradation induced by pVHL.
Kim JA; Choi DK; Min JS; Kang I; Kim JC; Kim S; Ahn JK
FEBS J; 2018 Jan; 285(1):115-126. PubMed ID: 29121446
[TBL] [Abstract][Full Text] [Related]
42. Topotecan blocks hypoxia-inducible factor-1alpha and vascular endothelial growth factor expression induced by insulin-like growth factor-I in neuroblastoma cells.
Beppu K; Nakamura K; Linehan WM; Rapisarda A; Thiele CJ
Cancer Res; 2005 Jun; 65(11):4775-81. PubMed ID: 15930297
[TBL] [Abstract][Full Text] [Related]
43. The VHL tumor suppressor in development and disease: functional studies in mice by conditional gene targeting.
Haase VH
Semin Cell Dev Biol; 2005; 16(4-5):564-74. PubMed ID: 15908240
[TBL] [Abstract][Full Text] [Related]
44. Tid-1 interacts with the von Hippel-Lindau protein and modulates angiogenesis by destabilization of HIF-1alpha.
Bae MK; Jeong JW; Kim SH; Kim SY; Kang HJ; Kim DM; Bae SK; Yun I; Trentin GA; Rozakis-Adcock M; Kim KW
Cancer Res; 2005 Apr; 65(7):2520-5. PubMed ID: 15805242
[TBL] [Abstract][Full Text] [Related]
45. Treatment with halofuginone results in marked growth inhibition of a von Hippel-Lindau pheochromocytoma in vivo.
Gross DJ; Reibstein I; Weiss L; Slavin S; Dafni H; Neeman M; Pines M; Nagler A
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3788-93. PubMed ID: 14506172
[TBL] [Abstract][Full Text] [Related]
46. The von hippel-lindau tumor suppressor protein: an update.
Kaelin WG
Methods Enzymol; 2007; 435():371-83. PubMed ID: 17998064
[TBL] [Abstract][Full Text] [Related]
47. VHL and PTEN loss coordinate to promote mouse liver vascular lesions.
Chen S; Sanford CA; Sun J; Choi V; Van Dyke T; Samulski RJ; Rathmell WK
Angiogenesis; 2010 Mar; 13(1):59-69. PubMed ID: 20221685
[TBL] [Abstract][Full Text] [Related]
48. MIR-92 stimulates VEGF by inhibiting von Hippel-Lindau gene product in epithelial ovarian cancer.
Guo FJ; Shao YP; Wang YP; Jin YM; Liu SS; Wang QY
J Biol Regul Homeost Agents; 2017 Jul-Sep,; 31(3):615-624. PubMed ID: 28952293
[TBL] [Abstract][Full Text] [Related]
49. von Hippel-Lindau gene plays a role during zebrafish pronephros development.
Chen YH; Chang CF; Lai YY; Sun CY; Ding YJ; Tsai JN
In Vitro Cell Dev Biol Anim; 2015 Nov; 51(10):1023-32. PubMed ID: 26194803
[TBL] [Abstract][Full Text] [Related]
50. Mutant IkappaBalpha suppresses hypoxia-induced VEGF expression through downregulation of HIF-1alpha and COX-2 in human glioma cells.
Kimba Y; Abe T; Wu JL; Inoue R; Fukiki M; Kohno K; Kobayashi H
Oncol Res; 2005; 15(3):139-49. PubMed ID: 16050135
[TBL] [Abstract][Full Text] [Related]
51. Renal cell carcinoma risk in type 2 von Hippel-Lindau disease correlates with defects in pVHL stability and HIF-1alpha interactions.
Knauth K; Bex C; Jemth P; Buchberger A
Oncogene; 2006 Jan; 25(3):370-7. PubMed ID: 16261165
[TBL] [Abstract][Full Text] [Related]
52. Immunoexpression patterns for Hypoxia-inducible Factor-1α and von Hippel-Lindau protein, in relation to Hsp90, of human brain tumors.
Assimakopoulou M; Androutsopoulou C; Zolota V; Matsoukas J
Histol Histopathol; 2016 May; 31(5):535-46. PubMed ID: 26592496
[TBL] [Abstract][Full Text] [Related]
53. Von Hippel-Lindau disease.
Kaelin WG
Annu Rev Pathol; 2007; 2():145-73. PubMed ID: 18039096
[TBL] [Abstract][Full Text] [Related]
54. Role of the VHL (von Hippel-Lindau) gene in renal cancer: a multifunctional tumour suppressor.
Nyhan MJ; O'Sullivan GC; McKenna SL
Biochem Soc Trans; 2008 Jun; 36(Pt 3):472-8. PubMed ID: 18481984
[TBL] [Abstract][Full Text] [Related]
55. Von Hippel-Lindau tumor suppressor protein and hypoxia-inducible factor in kidney cancer.
Maynard MA; Ohh M
Am J Nephrol; 2004; 24(1):1-13. PubMed ID: 14654728
[TBL] [Abstract][Full Text] [Related]
56. Effects of point mutations in pVHL on the binding of HIF-1α.
Domene C; Illingworth CJ
Proteins; 2012 Mar; 80(3):733-46. PubMed ID: 22105711
[TBL] [Abstract][Full Text] [Related]
57. Loss of vascular endothelial growth factor expression reduces vascularization, but not growth, of tumors lacking the Von Hippel-Lindau tumor suppressor gene.
Blouw B; Haase VH; Song H; Bergers G; Johnson RS
Oncogene; 2007 Jul; 26(31):4531-40. PubMed ID: 17297464
[TBL] [Abstract][Full Text] [Related]
58. Down-regulation of HIF-1alpha by oncolytic reovirus infection independently of VHL and p53.
Cho IR; Koh SS; Min HJ; Park EH; Ratakorn S; Jhun BH; Jeong SH; Yoo YH; Youn HD; Johnston RN; Chung YH
Cancer Gene Ther; 2010 May; 17(5):365-72. PubMed ID: 20075985
[TBL] [Abstract][Full Text] [Related]
59. USP9X destabilizes pVHL and promotes cell proliferation.
Zhang C; Peng Z; Zhu M; Wang P; Du X; Li X; Liu Y; Jin Y; McNutt MA; Yin Y
Oncotarget; 2016 Sep; 7(37):60519-60534. PubMed ID: 27517496
[TBL] [Abstract][Full Text] [Related]
60. The VHL tumor suppressor: master regulator of HIF.
Haase VH
Curr Pharm Des; 2009; 15(33):3895-903. PubMed ID: 19671042
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
